menu
    • menu
    [{"orgOrder":0,"company":"Xbrane Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Undisclosed","graph3":"Xbrane Biopharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Xbrane Biopharma \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Xbrane Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Xbrane Biopharma","sponsor":"Alvotech","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Antibody-drug Conjugate","year":"2025","type":"Acquisition","leadProduct":"Certolizumab Pegol","moa":"TNF-alpha","graph1":"Immunology","graph2":"Preclinical","graph3":"Xbrane Biopharma","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Xbrane Biopharma \/ Alvotech","highestDevelopmentStatusID":"4","companyTruncated":"Xbrane Biopharma \/ Alvotech"},{"orgOrder":0,"company":"Xbrane Biopharma","sponsor":"Biogen","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Antibody-drug Conjugate","year":"2022","type":"Licensing Agreement","leadProduct":"Certolizumab Pegol","moa":"TNF-alpha","graph1":"Immunology","graph2":"Preclinical","graph3":"Xbrane Biopharma","amount2":0.089999999999999997,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0.089999999999999997,"dosageForm":"Undisclosed","sponsorNew":"Xbrane Biopharma \/ Biogen","highestDevelopmentStatusID":"4","companyTruncated":"Xbrane Biopharma \/ Biogen"},{"orgOrder":0,"company":"Xbrane Biopharma","sponsor":"STADA Arzneimittel","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Ranibizumab","moa":"Vascular endothelial growth factor A","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Xbrane Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Xbrane Biopharma \/ STADA Arzneimittel","highestDevelopmentStatusID":"10","companyTruncated":"Xbrane Biopharma \/ STADA Arzneimittel"},{"orgOrder":0,"company":"Xbrane Biopharma","sponsor":"STADA Arzneimittel","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Ranibizumab","moa":"Vascular endothelial growth factor A","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Xbrane Biopharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Xbrane Biopharma \/ Xbrane Biopharma","highestDevelopmentStatusID":"15","companyTruncated":"Xbrane Biopharma \/ Xbrane Biopharma"},{"orgOrder":0,"company":"Xbrane Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Ranibizumab","moa":"Vascular endothelial growth factor A","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Xbrane Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Xbrane Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Xbrane Biopharma \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Xbrane Biopharma

    Menu

    Xbrane Biopharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Xbrane Biopharma

                            Sweden arrow
                            Neuroscience
                            Not Confirmed

                            Xbrane Biopharma

                            Sweden arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Certolizumab Pegol

                            Therapeutic Area : Immunology

                            Study Phase : Preclinical

                            Sponsor : Alvotech

                            Deal Size : $10.1 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Alvotech Acquires Xbrane’s R&D, Strengthening Biosimilars Leadership Globally

                            Details : Through the acquisition, Alvotech leverages R&D operations and a biosimilar candidate of Xbrane XB003 (certolizumab pegol). It is being evluated for treating crohn disease.

                            Product Name : Undisclosed

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : $10.1 million

                            March 20, 2025

                            Lead Product(s) : Certolizumab Pegol

                            Therapeutic Area : Immunology

                            Highest Development Status : Preclinical

                            Sponsor : Alvotech

                            Deal Size : $10.1 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Xbrane Biopharma

                            Sweden arrow
                            Neuroscience
                            Not Confirmed

                            Xbrane Biopharma

                            Sweden arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ranibizumab

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved FDF

                            Recipient : STADA Arzneimittel

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Stada and Xbrane Obtain British Approval for Ximluci® (ranibizumab) Biosimilar Referencing Lucentis®

                            Details : Ximluci (ranibizumab) binds and inhibits VEGF-A, including VEGF110, preventing the interaction of VEGF-A with VEGFR1 and VEGFR2 on the surface of endothelial cells, reducing endothelial cell proliferation, vascular leakage, and new blood vessel formation...

                            Product Name : Ximluci

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            January 16, 2023

                            Lead Product(s) : Ranibizumab

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved FDF

                            Recipient : STADA Arzneimittel

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Xbrane Biopharma

                            Sweden arrow
                            Neuroscience
                            Not Confirmed

                            Xbrane Biopharma

                            Sweden arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Certolizumab Pegol

                            Therapeutic Area : Immunology

                            Study Phase : Preclinical

                            Sponsor : Biogen

                            Deal Size : $88.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Biogen and Xbrane Announce Commercialization and License Agreement for Proposed Biosimilar Referencing CIMZIAÂ...

                            Details : Under the terms of the agreement, Biogen will gain exclusive global regulatory, manufacturing, and commercial rights to Xcimzaneâ„¢ and will be the Marketing Authorization Holder.

                            Product Name : Xcimzane

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : $8.0 million

                            February 07, 2022

                            Lead Product(s) : Certolizumab Pegol

                            Therapeutic Area : Immunology

                            Highest Development Status : Preclinical

                            Sponsor : Biogen

                            Deal Size : $88.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Xbrane Biopharma

                            Sweden arrow
                            Neuroscience
                            Not Confirmed

                            Xbrane Biopharma

                            Sweden arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Xbrane Has Initiated Development of Two New Biosimilar Candidates, Building an Oncology Biosimilar Portfolio T...

                            Details : Company has announced the initiation of developing two new biosimilar candidates referencing Keytruda® and Darzalex® respectively. Together with Xdivane™, these new biosimilar candidates form an oncology biosimilar portfolio.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            December 13, 2021

                            Lead Product(s) : Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Xbrane Biopharma

                            Sweden arrow
                            Neuroscience
                            Not Confirmed

                            Xbrane Biopharma

                            Sweden arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ranibizumab

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Xbrane Biopharma Plans to Continue Phase III Trial of its Xlucane® (Ranibizumab) Biosimilar Product

                            Details : The Xplore trial, which was started in 2019, is intended to study the biosimilarity of Xlucane as compared to Novartis’s Lucentis® in wet age-related macular degeneration (AMD).

                            Product Name : Xlucane

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            April 23, 2020

                            Lead Product(s) : Ranibizumab

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Xbrane Biopharma

                            Sweden arrow
                            Neuroscience
                            Not Confirmed

                            Xbrane Biopharma

                            Sweden arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ranibizumab

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : STADA Arzneimittel

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Comparing the Efficacy and Safety of Biosimilar Candidate Xlucane Versus Lucentis® in Patients With nAMD

                            Details : Ranibizumab is a Antibody drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Macular Degeneration.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            January 15, 2019

                            Lead Product(s) : Ranibizumab

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : STADA Arzneimittel

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth